vestigial like family member 1Genealiases: TDU · VGL1
Q-omics provides the consensus-scored VGLL1 profile across patient tissues and cancer cell-line models. VGLL1 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, VGLL1 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, VGLL1 RNA expression shows 11,500 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ACC, KIRC, and TGCT as cancer lineages where VGLL1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for VGLL1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes VGLL1 survival associations across molecular data types. VGLL1 RNA expression shows survival associations in the most cancer types (18), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible VGLL1 RNA expression–survival associations across cancer types. High VGLL1 expression shows unfavorable associations in ACC, UVM, PAAD, COAD and OV, but favorable associations in KIRP. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify ACC as the clearest survival context for VGLL1 RNA expression.
This table summarizes VGLL1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for VGLL1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. VGLL1 shows lower tumor expression in KIRC, KICH, KIRP and BRCA and higher tumor expression in THCA and BLCA. The KIRC box plot shows higher VGLL1 RNA expression in normal versus tumor tissue (log2 FC = −3.093, t-test p < 0.001).
This table shows molecular features associated with VGLL1 in patient tissues and cancer cell lines. In patient samples, VGLL1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, VGLL1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and OESOPHAGUS.
